4D Molecular Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, 4D Molecular Therapeutics sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 4 currently recruiting early-phase tilt top decile by trial count

4D Molecular Therapeutics: 9 sponsored US clinical trials, 4 recruiting.

4D Molecular Therapeutics sponsors 9 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting. 2 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is X-Linked Retinitis Pigmentosa, with 1 trials.

Top-decile sponsor footprint

4D Molecular Therapeutics ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 3

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

NCT07064759
RECRUITING Phase 3

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

NCT06864988
RECRUITING Phase 2

4D-710 in Adult Patients With Cystic Fibrosis

NCT05248230
RECRUITING Phase 1

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

NCT05197270
ACTIVE NOT RECRUITING Phase 2

4D-150 in Patients With Diabetic Macular Edema

NCT05930561
ACTIVE NOT RECRUITING Phase 1

An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease

NCT04519749
ACTIVE NOT RECRUITING Phase 1

4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)

NCT04517149
ACTIVE NOT RECRUITING Phase 1

Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia

NCT04483440
TERMINATED

"Natural History" Study of Choroideremia

NCT02994368

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 2
Phase 3 2

Therapeutic Areas

X-Linked Retinitis Pigmentosa 1
Macular Neovascularization Secondary to Age-Related Macular Degeneration 1
Cystic Fibrosis Lung 1
Diabetic Macular Edema 1
Fabry Disease 1
Choroideremia 1
Diabetic Retinopathy 1
Neovascular Age-related Macular Degeneration (nAMD) 1
Neovascular (Wet) Age-Related Macular Degeneration 1

What is open in the 4D Molecular Therapeutics pipeline

4 recruiting of 9 indexed (44% open).

Phase mix: 2 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: X-Linked Retinitis Pigmentosa (1 trial), 8 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

4D Molecular Therapeutics: open-pipeline peers nationwide

Peers matched on 9 registered trials and 44% open enrollment, not the therapeutic-area sidebar.

4D Molecular Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 51015202530 0%10%20%30%40%50% Total trials Recruiting share 4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyAcacia PharmaAmerican Heart AssociationAscendis Pharma A/SCullinan TherapeuticsMarquette University
4D Molecular Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

4D Molecular Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 44% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this 4D Molecular Therapeutics page

9 registered trials is a research-attention snapshot, not an endorsement of 4D Molecular Therapeutics or any single study.

  • 4 of 4D Molecular Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • X-Linked Retinitis Pigmentosa is the condition 4D Molecular Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See X-Linked Retinitis Pigmentosa trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. 4D Molecular Therapeutics pipeline card: 9 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.